These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35371720)

  • 1. Comparison of the Efficacy of Rosuvastatin 5 mg and 10 mg in Patients of Type 2 Diabetes Mellitus With Dyslipidemia.
    Aleem M; Zainab A; Hameed A; Khan AB; Ali SZ; Younus S
    Cureus; 2022 Feb; 14(2):e22595. PubMed ID: 35371720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast Growth Factor 21 and Its Association With Oxidative Stress and Lipid Profile in Type 2 Diabetes Mellitus.
    Aleem M; Maqsood H; Younus S; Zafar AF; Talpur AS; Shakeel H
    Cureus; 2021 Sep; 13(9):e17723. PubMed ID: 34659937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial.
    Dugani SB; Akinkuolie AO; Paynter N; Glynn RJ; Ridker PM; Mora S
    JAMA Cardiol; 2016 May; 1(2):136-45. PubMed ID: 27347563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New-Onset Type 2 Diabetes Mellitus.
    Younas A; Riaz J; Chughtai T; Maqsood H; Younus S; Qasim M; Saim M; Qazi S; Khaliq M; Fatima M
    Cureus; 2021 Jan; 13(1):e13045. PubMed ID: 33680590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of oral rosuvastatin intervention on HDL and its associated proteins in men with type 2 diabetes mellitus.
    Naresh S; Bitla AR; Rao PVLNS; Sachan A; Amancharla YL
    Endocrine; 2021 Jan; 71(1):76-86. PubMed ID: 32895874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
    Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
    Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative evaluation of safety and efficacy of rosuvastatin, simvastatin, and atorvastatin in patients of type 2 diabetes mellitus with dyslipidemia.
    Adsule SM; Baig MS; Gade PR; Khandelwal PN
    Int J Diabetes Dev Ctries; 2009 Apr; 29(2):74-9. PubMed ID: 20142872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
    Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
    Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of efficacy, safety, and cost-effectiveness of various statins in dyslipidemic diabetic patients.
    Bener A; Dogan M; Barakat L; Al-Hamaq AO
    Indian J Pharmacol; 2014; 46(1):88-93. PubMed ID: 24550591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of rosuvastatin in treatment of dyslipidemia.
    McKenney JM
    Am J Health Syst Pharm; 2005 May; 62(10):1033-47. PubMed ID: 15901588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.
    Olsson AG; McTaggart F; Raza A
    Cardiovasc Drug Rev; 2002; 20(4):303-28. PubMed ID: 12481202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Efficacy and Safety of Fixed Dose Combination of Rosuvastatin and Choline Fenofibrate to Fixed Dose Combination of Rosuvastatin and Fenofibrate in Patients of Mixed Dyslipidemia: A Randomized, Open-label, Multicentre Clinical Trial in Indian Population.
    Barkate H; Patel P; Shah D; Vyas F
    Indian J Endocrinol Metab; 2018; 22(5):627-631. PubMed ID: 30294571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of rosuvastatin on low-density lipoprotein subfractions in patients with impaired fasting glucose.
    Rizos CV; Kostapanos MS; Rizos EC; Tselepis AD; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2015 May; 20(3):276-83. PubMed ID: 25237153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Cost-Effectiveness, Safety, and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Dyslipidemic Diabetic Patients With or Without Metabolic Syndrome.
    Bener A; Dogan M; Barakat L; Al-Hamaq AO
    J Prim Care Community Health; 2014 Jul; 5(3):180-7. PubMed ID: 24522932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia.
    Katabami T; Murakami M; Kobayashi S; Matsui T; Ujihara M; Takagi S; Higa M; Ichijo T; Ohta A; Tanaka Y
    J Int Med Res; 2014 Apr; 42(2):457-67. PubMed ID: 24595147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
    Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A
    Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.